CN105424941B - Akr1b10蛋白和用于肝硬化诊断的试剂盒 - Google Patents
Akr1b10蛋白和用于肝硬化诊断的试剂盒 Download PDFInfo
- Publication number
- CN105424941B CN105424941B CN201510754922.6A CN201510754922A CN105424941B CN 105424941 B CN105424941 B CN 105424941B CN 201510754922 A CN201510754922 A CN 201510754922A CN 105424941 B CN105424941 B CN 105424941B
- Authority
- CN
- China
- Prior art keywords
- akr1b10
- antibody
- albumen
- kit
- diagnosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010019099 Aldo-Keto Reductase Family 1 member B10 Proteins 0.000 title claims abstract description 12
- 102100026451 Aldo-keto reductase family 1 member B10 Human genes 0.000 title claims abstract 9
- 208000019425 cirrhosis of liver Diseases 0.000 title claims description 17
- 238000003745 diagnosis Methods 0.000 title abstract description 18
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 13
- 238000013399 early diagnosis Methods 0.000 claims abstract description 11
- 210000002966 serum Anatomy 0.000 claims description 32
- 238000011895 specific detection Methods 0.000 claims description 9
- 235000013601 eggs Nutrition 0.000 claims 1
- 230000002440 hepatic effect Effects 0.000 abstract description 30
- 208000034189 Sclerosis Diseases 0.000 abstract description 29
- 238000011282 treatment Methods 0.000 abstract description 11
- 239000000427 antigen Substances 0.000 description 26
- 102000036639 antigens Human genes 0.000 description 26
- 108091007433 antigens Proteins 0.000 description 26
- 238000001514 detection method Methods 0.000 description 26
- 239000007788 liquid Substances 0.000 description 20
- 239000000523 sample Substances 0.000 description 14
- 238000004393 prognosis Methods 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 239000007853 buffer solution Substances 0.000 description 9
- 238000010790 dilution Methods 0.000 description 9
- 239000012895 dilution Substances 0.000 description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 8
- 239000003085 diluting agent Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000003018 immunoassay Methods 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 206010016654 Fibrosis Diseases 0.000 description 6
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000007882 cirrhosis Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 210000004408 hybridoma Anatomy 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 108010031132 Alcohol Oxidoreductases Proteins 0.000 description 4
- 102000005751 Alcohol Oxidoreductases Human genes 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 150000001299 aldehydes Chemical class 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 238000011091 antibody purification Methods 0.000 description 3
- 230000007910 cell fusion Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 108010084469 Aldo-Keto Reductases Proteins 0.000 description 2
- 102000005602 Aldo-Keto Reductases Human genes 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000007605 air drying Methods 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 238000009739 binding Methods 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000001447 compensatory effect Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 230000000873 masking effect Effects 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 239000012898 sample dilution Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 102000016912 Aldehyde Reductase Human genes 0.000 description 1
- 108010053754 Aldehyde reductase Proteins 0.000 description 1
- 101710145634 Antigen 1 Proteins 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 208000005331 Hepatitis D Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010041519 Spider naevus Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- -1 aldehyde ketone Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000010165 autogamy Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002038 chemiluminescence detection Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 238000013115 immunohistochemical detection Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 108700005880 mouse Akr1b10 Proteins 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 208000007232 portal hypertension Diseases 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- GOLXNESZZPUPJE-UHFFFAOYSA-N spiromesifen Chemical compound CC1=CC(C)=CC(C)=C1C(C(O1)=O)=C(OC(=O)CC(C)(C)C)C11CCCC1 GOLXNESZZPUPJE-UHFFFAOYSA-N 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/76—Chemiluminescence; Bioluminescence
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/08—Hepato-biliairy disorders other than hepatitis
- G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plasma & Fusion (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510754922.6A CN105424941B (zh) | 2015-11-09 | 2015-11-09 | Akr1b10蛋白和用于肝硬化诊断的试剂盒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510754922.6A CN105424941B (zh) | 2015-11-09 | 2015-11-09 | Akr1b10蛋白和用于肝硬化诊断的试剂盒 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105424941A CN105424941A (zh) | 2016-03-23 |
CN105424941B true CN105424941B (zh) | 2018-04-10 |
Family
ID=55503281
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510754922.6A Active CN105424941B (zh) | 2015-11-09 | 2015-11-09 | Akr1b10蛋白和用于肝硬化诊断的试剂盒 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105424941B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104059140A (zh) * | 2013-03-20 | 2014-09-24 | 湖南莱拓福生物科技有限公司 | Lolp-1蛋白和用于癌症的诊断等的试剂盒 |
JP7239139B2 (ja) * | 2018-08-03 | 2023-03-14 | 国立大学法人金沢大学 | 肝硬変の診断方法、非アルコール性脂肪肝炎及び肝細胞がんの合併症の診断方法並びに非アルコール性脂肪肝炎及び食道胃静脈瘤の合併症の診断方法 |
CN111239410A (zh) * | 2020-01-19 | 2020-06-05 | 湖南莱拓福生物科技有限公司 | 检测肝癌、肝炎和/或肝硬化的试剂盒及在akr1b10和afp联合定量测定中应用 |
CN114994318A (zh) * | 2022-06-16 | 2022-09-02 | 深圳上泰生物工程有限公司 | 一种用于检测akr1b10的试剂盒及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014105939A1 (en) * | 2012-12-27 | 2014-07-03 | Ngm Biopharmaceuticals, Inc. | Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
CN104059140A (zh) * | 2013-03-20 | 2014-09-24 | 湖南莱拓福生物科技有限公司 | Lolp-1蛋白和用于癌症的诊断等的试剂盒 |
CN104650234A (zh) * | 2014-10-27 | 2015-05-27 | 湖南莱拓福生物科技有限公司 | 抗akr1b10蛋白单克隆抗体及其应用 |
-
2015
- 2015-11-09 CN CN201510754922.6A patent/CN105424941B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014105939A1 (en) * | 2012-12-27 | 2014-07-03 | Ngm Biopharmaceuticals, Inc. | Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
CN104059140A (zh) * | 2013-03-20 | 2014-09-24 | 湖南莱拓福生物科技有限公司 | Lolp-1蛋白和用于癌症的诊断等的试剂盒 |
CN104650234A (zh) * | 2014-10-27 | 2015-05-27 | 湖南莱拓福生物科技有限公司 | 抗akr1b10蛋白单克隆抗体及其应用 |
Non-Patent Citations (2)
Title |
---|
RDA技术分析病毒性肝硬化、原发性肝细胞癌相关基因的研究;王怡;《中国优秀博硕士学位论文全文数据库(博士) 医药卫生科技辑》;20041215(第04期);摘要,第23-26页实验结果、第27页5-13行,表1-2 * |
二阶段化学诱发小鼠肝癌形成过程中PRX2,AKR1B10,E-FABP和67LR的表达研究;黄雪;《中国优秀硕士学位论文全文数据库 医药卫生科技辑》;20141015(第10期);摘要,第28-29页3.3.1(3)节、第33-35页3.3.2(2)节、第45-46页2.2节 * |
Also Published As
Publication number | Publication date |
---|---|
CN105424941A (zh) | 2016-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chalasani et al. | A novel blood-based panel of methylated DNA and protein markers for detection of early-stage hepatocellular carcinoma | |
CN104650234B (zh) | 抗akr1b10蛋白单克隆抗体及其应用 | |
CN102680698B (zh) | 中性粒细胞明胶酶相关脂质运载蛋白(ngal)测定试剂盒(胶乳增强免疫比浊法) | |
CN105424941B (zh) | Akr1b10蛋白和用于肝硬化诊断的试剂盒 | |
ES2380664B2 (es) | Método y dispositivo para el diagnóstico rápido de enfermedades en muestras fecales. | |
CN106885908A (zh) | 血清psmd4蛋白的检测试剂盒及其检测方法与应用 | |
CN104316685B (zh) | 一种二乙酰精胺的检测试剂盒及制备方法和应用 | |
CN102421799B (zh) | 用于高分子脂联素分析的新型单克隆抗体及其应用 | |
Zhang et al. | Development and application of diagnostics in the National Schistosomiasis Control Programme in the People's Republic of China | |
CN106706912A (zh) | 诊断炎症相关肝癌的标志物及其应用 | |
CN105588944A (zh) | 检测agp1、serpina3和cdh1含量的***在筛查活动性结核病患者中的应用 | |
CN105717308A (zh) | 快速定量检测粪便乳铁蛋白的免疫层析试剂盒 | |
Hayakawa et al. | Lactoferrin in gastrointestinal disease | |
CN101720434A (zh) | 肝病中的脂肪酸合酶 | |
CN114441760A (zh) | 一种用于肝癌诊断的生物标志物和试剂盒及检测方法 | |
Atta et al. | Value of serum anti-p53 antibodies as a prognostic factor in Egyptian patients with hepatocellular carcinoma | |
CN104459159A (zh) | 一种检测自身免疫肝病相关自身抗体谱的试剂盒 | |
CN102520176B (zh) | 一种定量检测白介素8的试剂盒 | |
CN106404731A (zh) | 一种同时检测细菌性和病毒性脑膜炎的pct与crp双标记时间分辨荧光免疫分析方法 | |
CN104330570B (zh) | 人热休克蛋白gp96在制备筛查肝病的产品中的应用 | |
JP2009536327A (ja) | 薬剤誘導肝臓損傷及び中毒性物質誘導肝臓損傷の同定及び早期同定並びに治療の同時観察のためのinvitro方法 | |
WO2017154839A1 (ja) | 肝細胞がん患者の再発リスク予測を補助する方法、装置、コンピュータプログラム製品及びキット | |
CN109085355A (zh) | 血清蛋白标志物组合在肺癌筛查和诊治中的应用 | |
CN108614119A (zh) | 一种尿液exosome的蛋白标记物的检测方法 | |
CN108761091A (zh) | 双抗夹心法快速检测hpv抗体的试纸条、试纸卡及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhu Yueqiu Inventor after: Lu Fengmin Inventor before: Zhu Yueqiu |
|
CB03 | Change of inventor or designer information | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: AKR1B10 protein and reagent kit for the diagnosis of liver cirrhosis Granted publication date: 20180410 Pledgee: Hunan Ningxiang Rural Commercial Bank Co.,Ltd. Industrial Park sub branch Pledgor: HUNAN LAITUOFU BIOTECHNOLOGY CO.,LTD. Registration number: Y2024980006689 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20180410 Pledgee: Hunan Ningxiang Rural Commercial Bank Co.,Ltd. Industrial Park sub branch Pledgor: HUNAN LAITUOFU BIOTECHNOLOGY CO.,LTD. Registration number: Y2024980006689 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: AKR1B10 protein and reagent kit for the diagnosis of liver cirrhosis Granted publication date: 20180410 Pledgee: Hunan Yuanjiang Rural Commercial Bank Co.,Ltd. Jinfu Branch Pledgor: HUNAN LAITUOFU BIOTECHNOLOGY CO.,LTD. Registration number: Y2024980019644 |